Results from a recent clinical trial show that adjuvant therapy with sunitinib (Sutent®) or sorafenib (Nexavar®) does not improve progression-free survival for patients with renal cell (kidney) cancer and may cause serious side effects.
Findings from the randomized, double-blind, placebo-controlled trial were published March 8 in The Lancet.
from Cancer via ola Kala on Inoreader http://ift.tt/1Mn8VHu
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου